CN101977923B - 抑制细胞生长的7-脱氮嘌呤核苷 - Google Patents
抑制细胞生长的7-脱氮嘌呤核苷 Download PDFInfo
- Publication number
- CN101977923B CN101977923B CN200980109880.3A CN200980109880A CN101977923B CN 101977923 B CN101977923 B CN 101977923B CN 200980109880 A CN200980109880 A CN 200980109880A CN 101977923 B CN101977923 B CN 101977923B
- Authority
- CN
- China
- Prior art keywords
- ddd
- nmr
- pyrimidine
- ribofuranosyl
- pyrrolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 OC[C@@]([C@@]1O)O[C@@](*2c3ncnc(-c4ccc[o]4)c3C=C2)[C@@]1O Chemical compound OC[C@@]([C@@]1O)O[C@@](*2c3ncnc(-c4ccc[o]4)c3C=C2)[C@@]1O 0.000 description 3
- YBUBCHDFOGAWME-QGMIFYJMSA-N OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2ncnc(-c3ccc[s]3)c2cc1 Chemical compound OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2ncnc(-c3ccc[s]3)c2cc1 YBUBCHDFOGAWME-QGMIFYJMSA-N 0.000 description 2
- UGVGEWMIRQEDEF-WHVJWXGYSA-N C[C@H]([C@@H]([C@@H](C(C1)(C1O)O)O)O)[n]1c2ncnc(-c3c[nH]cc3)c2cc1 Chemical compound C[C@H]([C@@H]([C@@H](C(C1)(C1O)O)O)O)[n]1c2ncnc(-c3c[nH]cc3)c2cc1 UGVGEWMIRQEDEF-WHVJWXGYSA-N 0.000 description 1
- VUBRYLFHJNXTMF-QGMIFYJMSA-N OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2ncnc(-c3c[o]cc3)c2c(F)c1 Chemical compound OC[C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2ncnc(-c3c[o]cc3)c2c(F)c1 VUBRYLFHJNXTMF-QGMIFYJMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
- H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
- H02J7/40—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data
- H02J7/44—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data between battery management systems and power sources
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
- H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
- H02J7/485—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries with provisions for charging different types of batteries
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Power Engineering (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2224708P | 2008-01-18 | 2008-01-18 | |
| US61/022,247 | 2008-01-18 | ||
| PCT/CZ2009/000004 WO2009089804A1 (en) | 2008-01-18 | 2009-01-15 | Novel cytostatic 7-deazapurine nucleosides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101977923A CN101977923A (zh) | 2011-02-16 |
| CN101977923B true CN101977923B (zh) | 2014-10-08 |
Family
ID=40434932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980109880.3A Active CN101977923B (zh) | 2008-01-18 | 2009-01-15 | 抑制细胞生长的7-脱氮嘌呤核苷 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8093226B2 (https=) |
| EP (2) | EP3133080B1 (https=) |
| JP (2) | JP5485172B2 (https=) |
| CN (1) | CN101977923B (https=) |
| AU (1) | AU2009204568B2 (https=) |
| CA (1) | CA2711384C (https=) |
| CY (2) | CY1118104T1 (https=) |
| DK (2) | DK2231689T3 (https=) |
| ES (2) | ES2693551T3 (https=) |
| HR (2) | HRP20161344T1 (https=) |
| HU (2) | HUE041598T2 (https=) |
| LT (2) | LT2231689T (https=) |
| NZ (1) | NZ586610A (https=) |
| PL (2) | PL2231689T3 (https=) |
| PT (2) | PT2231689T (https=) |
| SI (2) | SI3133080T1 (https=) |
| TR (1) | TR201815961T4 (https=) |
| WO (1) | WO2009089804A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| PT2421879E (pt) * | 2009-04-22 | 2013-12-09 | Acad Of Science Czech Republic | Novos 7-deazapurina nucleósidos para utilizações terapêuticas |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| SI2432472T1 (sl) * | 2009-05-22 | 2019-11-29 | Incyte Holdings Corp | 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| KR101817221B1 (ko) * | 2010-11-18 | 2018-01-10 | 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 | 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법 |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| CA3029170C (en) | 2016-06-29 | 2021-02-16 | Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. | Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use |
| CZ307334B6 (cs) | 2016-08-02 | 2018-06-13 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| CZ308104B6 (cs) | 2018-03-12 | 2020-01-08 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. | Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| WO2020206289A1 (en) * | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| CN114008064A (zh) * | 2019-06-18 | 2022-02-01 | 大鹏药品工业株式会社 | 具有吡咯并嘧啶骨架的新型的磷酸酯化合物或其药学上可接受的盐 |
| CN115515593A (zh) * | 2020-02-17 | 2022-12-23 | 勒芬天主教大学 | 作为药物的新的6-取代的7-脱氮嘌呤和相应的核苷 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN112190590A (zh) * | 2020-11-06 | 2021-01-08 | 牡丹江医学院 | 一种治疗动脉粥样硬化的硒核苷及其药物组合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003051899A1 (en) * | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
| CN1863813A (zh) * | 2003-08-27 | 2006-11-15 | 生物区股份有限公司 | 作为治疗剂的新型三环核苷或核苷酸 |
| CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS50125033A (https=) * | 1974-03-19 | 1975-10-01 | ||
| IL108523A0 (en) | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| JPH10158293A (ja) * | 1996-08-08 | 1998-06-16 | Rikagaku Kenkyusho | ３’−デオキシリボヌクレオチド誘導体 |
| JP3489991B2 (ja) * | 1997-07-07 | 2004-01-26 | 理化学研究所 | ３’−デオキシリボヌクレオチド誘導体 |
| JP3318579B2 (ja) * | 1997-07-07 | 2002-08-26 | 理化学研究所 | Ｄｎａの塩基配列決定方法 |
| CZ9901996A3 (cs) * | 1999-06-04 | 2001-01-17 | Ústav organické chemie a biochemie AV ČR | Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují |
| EP1804812A4 (en) * | 2004-10-21 | 2009-09-02 | Merck & Co Inc | FLUORINATED PYRROLO [2,3-D] PYRIMIDIN NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS |
| US7405204B2 (en) * | 2005-04-25 | 2008-07-29 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
-
2009
- 2009-01-15 PT PT97028427T patent/PT2231689T/pt unknown
- 2009-01-15 HR HRP20161344TT patent/HRP20161344T1/hr unknown
- 2009-01-15 CN CN200980109880.3A patent/CN101977923B/zh active Active
- 2009-01-15 SI SI200931882T patent/SI3133080T1/sl unknown
- 2009-01-15 DK DK09702842.7T patent/DK2231689T3/en active
- 2009-01-15 LT LTEP09702842.7T patent/LT2231689T/lt unknown
- 2009-01-15 AU AU2009204568A patent/AU2009204568B2/en active Active
- 2009-01-15 LT LTEP16174985.8T patent/LT3133080T/lt unknown
- 2009-01-15 EP EP16174985.8A patent/EP3133080B1/en active Active
- 2009-01-15 HU HUE16174985A patent/HUE041598T2/hu unknown
- 2009-01-15 ES ES16174985.8T patent/ES2693551T3/es active Active
- 2009-01-15 NZ NZ586610A patent/NZ586610A/xx unknown
- 2009-01-15 HU HUE09702842A patent/HUE030767T2/en unknown
- 2009-01-15 WO PCT/CZ2009/000004 patent/WO2009089804A1/en not_active Ceased
- 2009-01-15 ES ES09702842.7T patent/ES2598503T3/es active Active
- 2009-01-15 JP JP2010542509A patent/JP5485172B2/ja active Active
- 2009-01-15 US US12/354,432 patent/US8093226B2/en active Active
- 2009-01-15 PT PT16174985T patent/PT3133080T/pt unknown
- 2009-01-15 EP EP09702842.7A patent/EP2231689B1/en active Active
- 2009-01-15 PL PL09702842T patent/PL2231689T3/pl unknown
- 2009-01-15 SI SI200931535A patent/SI2231689T1/sl unknown
- 2009-01-15 PL PL16174985T patent/PL3133080T3/pl unknown
- 2009-01-15 DK DK16174985.8T patent/DK3133080T3/en active
- 2009-01-15 TR TR2018/15961T patent/TR201815961T4/tr unknown
- 2009-01-15 CA CA2711384A patent/CA2711384C/en active Active
-
2013
- 2013-12-25 JP JP2013266910A patent/JP2014058567A/ja not_active Withdrawn
-
2016
- 2016-10-19 CY CY20161101041T patent/CY1118104T1/el unknown
-
2018
- 2018-10-29 HR HRP20181774TT patent/HRP20181774T1/hr unknown
- 2018-10-30 CY CY20181101120T patent/CY1121364T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003051899A1 (en) * | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
| CN1863813A (zh) * | 2003-08-27 | 2006-11-15 | 生物区股份有限公司 | 作为治疗剂的新型三环核苷或核苷酸 |
| CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
Non-Patent Citations (4)
| Title |
|---|
| Bheemarao G.Ugarkar,等.Adenosine Kinase Inhibitors. 3. Synthesis, SAR, and Antiinflammatory Activity of a Series of L-Lyxofuranosyl Nucleosides.《J.Med.Chem.》.2003,第46卷4750-4760. * |
| CAMILLA M.SMITH,等.IMPROVED METHODS FOR THE STUDY OF DRUG EFFECTS ON PURINE METABOLISM AND THEIR APPLICATION TO NEBULARINE AND 7-DEAZANEBULARINE.《Biochemical Pharmacology》.1974,第23卷2020-2035. * |
| Nucleic Acid Related Compounds. 86. Nucleophilic Functionalization of Adenine, Adenosine, Tubercidin, and Formycin Derivatives via Elaboration of the Heterocyclic Amino Group into a Readily Displaced 1,2,4-Triazol-4-y1 Substituent;Robert W.Miles，等;《J.Am.Chem.SOC.》;19951231;第117卷(第22期);5951-5957 * |
| STRUCTURE-ACTIVITY RELATIONSHIP FOR THE BINDING OF NUCLEOSIDE LIGANDS TO ADENOSINE KINASE FROM TOXOPLASMA GONDII;MAX H ILTZSCH，等;《Biochemical Pharmacology》;19950101;第49卷(第10期);1501-1512 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101977923B (zh) | 抑制细胞生长的7-脱氮嘌呤核苷 | |
| CN104497084B (zh) | 用于治疗用途的7-脱氮嘌呤核苷 | |
| HK1209129B (zh) | 用於治疗用途的7-脱氮嘌呤核苷 | |
| HK1234411A1 (en) | Novel cytostatic 7-deazapurine nucleosides | |
| HK1234411B (en) | Novel cytostatic 7-deazapurine nucleosides | |
| HK1149016B (en) | Novel cytostatic 7-deazapurine nucleosides | |
| HK1166325B (en) | Novel 7-deazapurine nucleosides for therapeutic uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |